drugset / Trial / NCT02017535

An Adaptive Treatment Strategy for Adolescent Depression-Continuation

NCT02017535

Phase 1/2 Completed 15 enrolled University of Minnesota
RandomizedParallel-groupSingle-blindHealth-services research

Summary

Aim 1: Assess the feasibility and acceptability of the personalized continuation treatment strategy. Aim 2: Estimate variances of primary and secondary outcomes with the continuation treatment. Aim 3: Conduct exploratory hypothesis-generating analyses to inform further development of the personalized continuation treatment strategy to be tested in a subsequent R01 proposal.

Timeline

Start
2012-06
Primary completion
2018-10-01
Completion
2018-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluoxetine Small molecule 20 mg Oral
Subject Fluoxetine Small molecule 60 mg Oral

Indications

No indication recorded.